Clinical trial · no report yet · Phase 1
NCT02950766
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
- NCT02950766 ↗
- Active, not recruiting
- Patrick Ott, MD, PhD
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Kidney Cancer
- Interventions
- NeoVax; Ipilimumab
- Arms
- Neovax in Combination with Ipilimumab · Experimental
- NeoVax alone · Experimental
- Enrollment
- 19 (estimated)
- Primary outcomes
- Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0
- Sponsor
- Patrick Ott, MD, PhD with Bristol-Myers Squibb, Oncovir, Inc.
- Start
- Mar 3, 2019
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02950766 · updated Feb 3, 2026
Publications
linked from the registry- Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Mar;639(8054):474-482. doi: 10.1038/s41586-024-08507-5. Epub 2025 Feb 5. PubMed 39910301